# Multiple Ascending Doses (MAD) of Anti-A Disintegrin and Metalloproteinase With Thrombospondin Motifs-5 (Anti-ADAMTS-5) Nanobody in Participants With Knee Osteoarthritis (OA)

> **NCT03583346** · PHASE1 · COMPLETED · sponsor: **Merck KGaA, Darmstadt, Germany** · enrollment: 32 (actual)

## Conditions studied

- Osteoarthritis, Knee

## Interventions

- **DRUG:** M6495
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03583346
- **Lead sponsor:** Merck KGaA, Darmstadt, Germany
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-08-23
- **Primary completion:** 2019-07-31
- **Final completion:** 2019-07-31
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2020-01-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03583346

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03583346, "Multiple Ascending Doses (MAD) of Anti-A Disintegrin and Metalloproteinase With Thrombospondin Motifs-5 (Anti-ADAMTS-5) Nanobody in Participants With Knee Osteoarthritis (OA)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03583346. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*